These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 28375169)
21. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Barthel H; Cleij MC; Collingridge DR; Hutchinson OC; Osman S; He Q; Luthra SK; Brady F; Price PM; Aboagye EO Cancer Res; 2003 Jul; 63(13):3791-8. PubMed ID: 12839975 [TBL] [Abstract][Full Text] [Related]
22. A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688. Kostakoglu L; Duan F; Idowu MO; Jolles PR; Bear HD; Muzi M; Cormack J; Muzi JP; Pryma DA; Specht JM; Hovanessian-Larsen L; Miliziano J; Mallett S; Shields AF; Mankoff DA; J Nucl Med; 2015 Nov; 56(11):1681-9. PubMed ID: 26359256 [TBL] [Abstract][Full Text] [Related]
23. Evaluation of the Performance of 18F-Fluorothymidine Positron Emission Tomography/Computed Tomography (18F-FLT-PET/CT) in Metastatic Brain Lesions. Nikaki A; Papadopoulos V; Valotassiou V; Efthymiadou R; Angelidis G; Tsougos I; Prassopoulos V; Georgoulias P Diagnostics (Basel); 2019 Jan; 9(1):. PubMed ID: 30691084 [TBL] [Abstract][Full Text] [Related]
24. Comparison of 4'-[methyl-(11)C]thiothymidine ((11)C-4DST) and 3'-deoxy-3'-[(18)F]fluorothymidine ((18)F-FLT) PET/CT in human brain glioma imaging. Toyota Y; Miyake K; Kawai N; Hatakeyama T; Yamamoto Y; Toyohara J; Nishiyama Y; Tamiya T EJNMMI Res; 2015; 5():7. PubMed ID: 25853013 [TBL] [Abstract][Full Text] [Related]
25. PET imaging of proliferation with pyrimidines. Tehrani OS; Shields AF J Nucl Med; 2013 Jun; 54(6):903-12. PubMed ID: 23674576 [TBL] [Abstract][Full Text] [Related]
26. Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma. Schöder H; Zelenetz AD; Hamlin P; Gavane S; Horwitz S; Matasar M; Moskowitz A; Noy A; Palomba L; Portlock C; Straus D; Grewal R; Migliacci JC; Larson SM; Moskowitz CH J Nucl Med; 2016 May; 57(5):728-34. PubMed ID: 26719374 [TBL] [Abstract][Full Text] [Related]
29. FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab. Scarpelli M; Zahm C; Perlman S; McNeel DG; Jeraj R; Liu G J Immunother Cancer; 2019 Jan; 7(1):23. PubMed ID: 30700328 [TBL] [Abstract][Full Text] [Related]
30. A Subset of Non-Small Cell Lung Cancer Patients Treated with Pemetrexed Show Aravind P; Popat S; Barwick TD; Soneji N; Lythgoe M; Sreter KB; Lozano-Kuehne JP; Bergqvist M; Patel N; Aboagye EO; Kenny LM Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509378 [TBL] [Abstract][Full Text] [Related]
31. Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma. Lee H; Kim SK; Kim YI; Kim TS; Kang SH; Park WS; Yun T; Eom HS J Nucl Med; 2014 Feb; 55(2):216-22. PubMed ID: 24365650 [TBL] [Abstract][Full Text] [Related]
32. 3'-Deoxy-3'-(18F) Fluorothymidine Positron Emission Tomography/Computed Tomography in Non-small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy: A Pilot Study. Lewis S; Chan M; Weiss J; Raziee H; Driscoll B; Bezjak A; Sun A; Lok B; Vines D; Cho J; Bissonnette JP; Raman S; Hope A; Giuliani M Adv Radiat Oncol; 2022; 7(6):101037. PubMed ID: 36420186 [TBL] [Abstract][Full Text] [Related]
33. FLT-PET At 6 Weeks Predicts Response Assessed by CT at 12 Weeks in Melanoma Patients Treated With Pembrolizumab. Yeh R; Trager MH; Rizk EM; Finkel GG; Barker LW; Carvajal RD; Geskin LJ; Schwartz GK; Schwartz L; Dercle L; Saenger YM Clin Nucl Med; 2020 Apr; 45(4):267-275. PubMed ID: 32108700 [TBL] [Abstract][Full Text] [Related]
34. A pilot study to evaluate 3'-deoxy-3'-18F-fluorothymidine pet for initial and early response imaging in mantle cell lymphoma. Herrmann K; Buck AK; Schuster T; Rudelius M; Wester HJ; Graf N; Scheuerer C; Peschel C; Schwaiger M; Dechow T; Keller U J Nucl Med; 2011 Dec; 52(12):1898-902. PubMed ID: 22065875 [TBL] [Abstract][Full Text] [Related]
35. 3'-Deoxy-3'-[18F]fluorothymidine positron emission tomography imaging of thymidine kinase 1 activity after 5-fluorouracil treatment in a mouse tumor model. Hong IK; Kim SY; Chung JH; Lee SJ; Oh SJ; Lee SJ; Oh J; Ryu JS; Kim TW; Kim DY; Moon DH Anticancer Res; 2014 Feb; 34(2):759-66. PubMed ID: 24511010 [TBL] [Abstract][Full Text] [Related]
36. Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation. Barwick T; Bencherif B; Mountz JM; Avril N Nucl Med Commun; 2009 Dec; 30(12):908-17. PubMed ID: 19794320 [TBL] [Abstract][Full Text] [Related]
37. Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity. Troost EG; Bussink J; Slootweg PJ; Peeters WJ; Merkx MA; van der Kogel AJ; Oyen WJ; Kaanders JH J Nucl Med; 2010 May; 51(5):713-9. PubMed ID: 20395329 [TBL] [Abstract][Full Text] [Related]
38. Glioma proliferation as assessed by 3'-fluoro-3'-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma. Ullrich R; Backes H; Li H; Kracht L; Miletic H; Kesper K; Neumaier B; Heiss WD; Wienhard K; Jacobs AH Clin Cancer Res; 2008 Apr; 14(7):2049-55. PubMed ID: 18381944 [TBL] [Abstract][Full Text] [Related]
39. Early response assessment using 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Herrmann K; Wieder HA; Buck AK; Schöffel M; Krause BJ; Fend F; Schuster T; Meyer zum Büschenfelde C; Wester HJ; Duyster J; Peschel C; Schwaiger M; Dechow T Clin Cancer Res; 2007 Jun; 13(12):3552-8. PubMed ID: 17575218 [TBL] [Abstract][Full Text] [Related]